Anil Patel, MD
Allergy & Immunology · Newtown, PANPI 1396034369
Payments from drug & device makers
Across 553 payments — averaging $25.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$3K
- GSK$2K
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Optinose US, Inc.$502
- AbbVie$475
- plus $5K from 31 others
What the payments were for
- Consulting fees$1,44610%
- Food & beverage$12,58188%
- Education$2422%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 50 | $2,702 |
| GSK | 117 | $2,452 |
| AstraZeneca | 84 | $2,067 |
| Regeneron Healthcare Solutions, Inc. | 58 | $1,261 |
| Optinose US, Inc. | 19 | $502 |
| AbbVie(2 entities) | 16 | $475 |
| Genentech USA, Inc. | 16 | $460 |
| Alk-abello, Inc | 21 | $452 |
| Kaleo, Inc. | 24 | $445 |
| Pfizer | 30 | $423 |
| Amgen(2 entities) | 13 | $384 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $369 |
| Aimmune Therapeutics, Inc. | 11 | $295 |
| Novartis | 14 | $269 |
| Boehringer Ingelheim | 8 | $232 |
| CSL Behring | 8 | $220 |
| Grifols USA, LLC | 6 | $143 |
| Shire North American Group Inc | 1 | $122 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $121 |
| Teva Pharmaceuticals USA, Inc. | 8 | $121 |
| Circassia Inc. | 1 | $97 |
| Organon | 4 | $76 |
| Incyte Corporation | 3 | $74 |
| Covis Pharma GmbH | 3 | $70 |
| Mallinckrodt Hospital Products Inc. | 2 | $58 |
| Hikma Pharmaceuticals USA | 3 | $57 |
| Blueprint Medicines Corporation | 3 | $51 |
| Pharming Healthcare, Inc. | 2 | $47 |
| Greer Laboratories, Inc. | 1 | $40 |
| Phadia US Inc. | 2 | $37 |
| Paratek Pharmaceuticals, Inc. | 1 | $27 |
| Cycle Pharmaceuticals Inc | 1 | $27 |
| LEO Pharma Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $20 |
| USWM, LLC | 1 | $16 |
| Biocryst US Sales Co., LLC | 1 | $16 |
| Bio Products Laboratory USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,269 in reported general payments places this provider in the 75th percentile of 175 allergy & immunology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $52,378 |
| Breo ElliptaFluticasone/Vilanterol | 80 | $49,638 |
| Dupixent PenDupilumab | 12 | $49,355 |
| XolairOmalizumab | 11 | $49,083 |
| Arnuity ElliptaFluticasone Furoate | 76 | $27,606 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 71 | $14,473 |
| Spiriva RespimatTiotropium Bromide | 18 | $13,463 |
| Qvar RedihalerBeclomethasone Dipropionate | 26 | $9,721 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $9,219 |
| Advair HfaFluticasone Propion/Salmeterol | 22 | $9,154 |
| Epinephrine | 45 | $8,271 |
| Azelastine Hcl | 261 | $7,618 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 161 | $6,053 |
| QnaslBeclomethasone Dipropionate | 16 | $5,819 |
| Wixela InhubFluticasone Propion/Salmeterol | 28 | $5,590 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $2,452 | $129,623210 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler, Qnasl | $121 | $15,54142 claims |
| Boehringer IngelheimSpiriva Respimat | $232 | $13,46318 claims |
| AstraZenecaSymbicort | $2,067 | $9,21926 claims |
| Hikma Pharmaceuticals USAEpinephrine | $57 | $8,27145 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 175 allergy & immunology providers in Pennsylvania.
Other allergy & immunology in Newtown
- Drew WeissmanPhiladelphia$15.3M
- Timothy CraigHershey$2M
- Eric SchenkelBethlehem$845K
- Sergei BelenkyPittsburgh$775K
- Sandra GawchikUpland$390K
- Anthony RooklinGlen Mills$319K
- Corinna BowserNarberth$229K
- Thomas KleinHavertown$222K
- Rahul DattaPhiladelphia$198K
- Shailen ShahCollegeville$183K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.